KALTF - Claritas inks new partnership with Scientia for early-stage study for R-107

Claritas Pharmaceuticals (OTCPK:KALTF) announced it has ended its partnership with CMAX Clinical Research for a Phase 1 study on R-107, the company’s experimental liquid, nitric oxide-releasing compound. The company has inked a clinical trial research agreement with Australia-based Scientia Clinical Research to complete the study in Q1 2022. CEO Robert Farrell highlighted the tax benefits in its decision to conduct the study in Australia noting that The Australian Taxation Office offers rebates for companies at a rate of ~44% of qualifying R&D expenses. “We were unwilling to delay the completion of the Phase 1 Study beyond the end of Q1 2022, and for this reason we have moved the Phase 1 Study from CMAX in Adelaide to Scientia in Sydney,” Farrell added. In April, Claritas (OTCPK:KALTF) and CMAX partnered to conduct the randomized, placebo-controlled study in Adelaid.

For further details see:

Claritas inks new partnership with Scientia for early-stage study for R-107